Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label Extension Study of Onartuzumab in Solid Tumors
jRCT2080222922Phase 3
- Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Start
- Jul 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label trial of onartuzumab in Nonhematologic neoplasms (2 arms), sponsored by Chugai Pharmaceutical Co., Ltd.
02
Drugs
onartuzumab
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on jRCT2080222922.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080222922.